Clinical Trial Update: Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating universal CAR-T cells (REVO-UWD-19) for refractory or relapsed B-cell malignancies is currently recruiting, sponsored by Wondercel Bi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Leukemia
• B-cell Lymphoma
• B-cell Malignancy

Drugs mentioned

• REVO-UWD-19 universal CAR-T cells (REVO-UWD-19 CAR-T cells)

Snippet

Sponsor: Wondercel Biotech (ShenZhen) | Conditions: B Cell Lymphoma, B Cell Leukemia | EARLY_Phase 1 | Status: RECRUITING